MeSH tree: D12.644.548.275.001
The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. ...
Feb 11, 2026
0
8
GLP-1 drugs have ushered in a new era in weight loss.
Feb 7, 2026
0
26
In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: "Can you believe we finally ...
Feb 3, 2026
0
12
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight ...
Jan 23, 2026
0
17
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
Jan 22, 2026
0
16
Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.
Jan 15, 2026
0
12
When endocrinologist Dan Bessesen, MD, looked online and saw how easy it would be for him to purchase a weight loss drug from a compounding pharmacy without being seen by a medical provider, he was disturbed.
Jan 14, 2026
0
11
Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year.
Jan 13, 2026
0
10
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimens, new research found Thursday.
Jan 11, 2026
0
67
Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which most drugs and interventions in the U.S. are approved.
Jan 10, 2026
0
15
